High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial

4704 Background: Cox-2 expression has angiogenic and cytoprotective effects and its suppression could increase the response to chemotherapy. Cox-2 is overexpressed in 89.3% of pts with prostate can...